MedTrace Logo

Exploring the Diagnostic Biomarkers of Cognitive Disorders in China

NCT06419101 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2024-11-14

No results posted yet for this study

Summary

Dementia is a syndrome characterized by progressive global cognitive impairment that impairs occupational, family, or social functioning. It detrimentally affects personal health and quality of life, imposing significant medical economy, social and psychological burden on the countries and the patients' family. The internationally renowned dementia cohort includes the DIAN that focused on genetics studies, the ADNI cohort featuring imaging and the FINGERS cohort focused on risk factor intervention, etc. Establishing standardized and shared longitudinal follow-up dementia cohorts and clinical database is an essential challenge for constructing dementia cohort in China. Moreover, there is a lack of large-scale prospective longitudinal follow-up cohorts within the Chinese population that cover subjective cognitive decline (SCD) to explore biomarkers with diagnostic and early warning value for different kinds of dementia and pre-dementia stages. The study will rely on the dementia cohort based on Chinese population to explore the biological phenotype characteristics of the pre-dementia stage and different dementia subtypes, and observe the dynamic change rules of the dementia cohort vertically, so as to foster early intervention and improve prognosis for individuals with dementia.

Conditions

Sponsors & Collaborators

  • First Hospital of Shijiazhuang City

    collaborator OTHER

  • Chongqing Medical University

    collaborator OTHER

  • Tianjin Huanhu Hospital

    collaborator OTHER

  • Qianfoshan Hospital

    collaborator OTHER

  • Cuibai Wei，Clinical Professor

    lead OTHER

Principal Investigators

  • Cuibai Wei · Xuan Wu Hospital of Capital Medical University, Beijing, China, 100053

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-30
Primary Completion
2034-05-10
Completion
2035-05-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06419101 on ClinicalTrials.gov